WO1997033577A1 - Method for treating bipolar disorder - Google Patents
Method for treating bipolar disorder Download PDFInfo
- Publication number
- WO1997033577A1 WO1997033577A1 PCT/US1996/019575 US9619575W WO9733577A1 WO 1997033577 A1 WO1997033577 A1 WO 1997033577A1 US 9619575 W US9619575 W US 9619575W WO 9733577 A1 WO9733577 A1 WO 9733577A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bipolar disorder
- olanzapine
- effective amount
- treating
- patient
- Prior art date
Links
- 208000020925 Bipolar disease Diseases 0.000 title claims abstract description 44
- 238000000034 method Methods 0.000 title claims abstract description 28
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims abstract description 45
- 229960005017 olanzapine Drugs 0.000 claims abstract description 45
- 208000024714 major depressive disease Diseases 0.000 claims abstract description 9
- 238000011282 treatment Methods 0.000 claims description 17
- 206010026749 Mania Diseases 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 7
- 238000002441 X-ray diffraction Methods 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 description 15
- 239000004480 active ingredient Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 5
- 208000028017 Psychotic disease Diseases 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- -1 4-methyl-l-piperazinyl Chemical group 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000000634 powder X-ray diffraction Methods 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- 230000003001 depressive effect Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002411 thermogravimetry Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 1
- 108091005479 5-HT2 receptors Proteins 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000020186 Schizophreniform disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical group COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000012066 reaction slurry Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 1
- 229950001675 spiperone Drugs 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Definitions
- This invention provides a method for using 2- methyl-4- (4-methyl-l-piperazinyl) -lOH-thieno[2,3-b] [1,5] benzodiazepine, (hereinafter referred as "olanzapine”), for the treatment of bipolar disorder.
- Bipolar Disorder is a psychiatric condition which is prevelant across cultures and age groups. The lifetime prevalence of Bipolar Disorder can be as high as 1.6%. DSM- IV. p. 353 (American Psychiatric Association, Washington, D.C. 1994) . Bipolar Disorder is a recurrent disorder characterized by one or more Manic Episodes immediately before or after a Major Depressive Episode or may be characterized by one or more Major Depressive Episodes accompanied by at least one Hypomanic Episode. Additionally, the symptoms must cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.
- Bipolar Disorder In some cases the Hypomanic Episodes themselves do not cause impairment; however, the impairment may result from the Major Depressive Episodes or from a chronic pattern of unpredictable mood episodes and fluctuating unreliable interpersonal and occupational functioning.
- the symptoms of Bipolar Disorder must not be better accounted for by a psychotic condition or due to the direct physiological effects of a medication, other somatic treatments for depression, drugs of abuse, or toxin exposure.
- Bipolar Disorder is associated with a significant risk of completed suicide. Further, the patient suffering from Bipolar Disorder is likely to suffer from school truancy, school failure, occupational failure, or divorce. Therefore, Bipolar Disorder is a serious, fairly prevelant, psychological condition which is clearly distinguished from psychotic conditions such as schizophrenia.
- DSM-IV. p. 353 American Psychiatric Association, Washington, D.C. 1994
- DSM-IV. p. 353 American Psychiatric Association, Washington, D.C. 1994
- DSM-IV. p. 353 American Psychiatric Association, Washington, D.C
- olanzapine can provide antipsychotic activity and is currently undergoing investigation for this purpose.
- Olanzapine is a known compound and described in U.S. Patent No. 5,229,382 as being useful for the treatment of schizophrenia, schizophreniform disorder, acute mania, mild anxiety states, and psychosis.
- U.S. Patent No. 5,229,382 is herein incorporated by reference in its entirety.
- olanzapine was not known to be useful for the treatment of Bipolar Disorder. Applicants have discovered that olanzapine can be useful for the treatment of bipolar disorder. Olanzapine could address a long felt need for treatments which provide a favorable safety profile and effectively provide relief for the patient suffering from Bipolar Disorder.
- olanzapine can be useful for treating Bipolar Disorder, Major Depressive Episode.
- olanzapine can be a useful treatment for Bipolar Disorder wherein the Bipolar Disorder is not characterized by a manic episode.
- the presently claimed invention provides a method for treating bipolar disorder, comprising administering an effective amount of olanzapine or a pharmaceutically acceptable salt thereof to a patient in need of such treatment.
- the present invention provides a method for treating depressive/depressive bipolar disorder, comprising administering an effective amount of olanzapine or a pharmaceutically acceptable salt thereof to a patient in need of such treatment.
- the present invention provides a method for treating Bipolar Disorder, Major Depressive episode, comprising administering an effective amount of olanzapine or a pharmaceutically acceptable salt thereof to a patient in need of such treatment.
- Olanzapine is of the formula
- Bipolar Disorder involves at least one manic episode; however, some patients suffering from Bipolar Disorder experience Major Depressive episodes.
- the present invention provides a method for treating the patient suffering from or susceptible to Bipolar Disorder, wherein the patient fails to experience a manic episode.
- olanzapine will be the Form II olanzapine polymorph having a typical x-ray powder diffraction pattern as represented by the following interplanar spacings:
- a typical example of an x-ray diffraction pattern for Form II is as follows wherein d represents the interplanar spacing and I/I ⁇ represents the typical relative intensities: d ⁇ /i ⁇
- substantially pure refers to Form II associated with less than about 5% Form I, preferably less than about 2% Form I, and more preferably less than about 1% Form I. Further, “substantially pure” Form II will contain less than about 0.5% related substances, wherein “related substances” refers to undesired chemical impurities or residual solvent or water.
- the polymorph obtainable by the process taught in the '382 patent will be designated as Form I and has a typical x-ray powder diffraction pattern substantially as follows, obtained using a Siemens D5000 x-ray powder diffractometer, wherein d represents the interplanar spacing:
- the interplanar spacings in the column marked “d” are in Angstroms.
- the typical relative intensities are in the column marked "I/Ii”.
- the term “mammal” shall refer to the Mammalia class of higher vertebrates.
- the term “mammal” includes, but is not limited to, a human.
- the term “treating” as used herein includes prophylaxis of the named condition or amelioration or elimination of the condition once it has been established.
- Bipolar Disorder shall refer to a condition characterized as a Bipolar Disorder, in the DSM-IV-R. Diagnostic and Statistical Manual of Mental Disorders. Revised. 3rd Ed. (1994) as catagory 296.xx. To further clarify. Applicants contemplate the treatment of both Bipolar Disorder I and Bipolar disorder II as described in the DSM-IV-R.
- the DSM-IV-R was prepared by the Task Force on Nomenclature and Statistics of the American Psychiatric
- olanzapine has muscarinic cholinergic receptor activity.
- the compound is active at the dopamine D-l and D-2 receptors as indicated by an IC50 of less than 1 uM in the 3H-SCH233390 (Billard, et al. Life Sciences 35:1885 (1984)) and the 3H spiperone (Seeman et al Nature 216:717 (1976)) binding assays respectively.
- olanzapine is active at the 5-HT-2 receptor and 5-HTlC receptor.
- the complex pharmacological profile of the compound provides a medicament which can be useful for the treatment of Bipolar Disorder. The usefulness of the compound for treating a
- Olanzapine is effective over a wide dosage range, the actual dose administered being dependent on the condition being treated. For example, in the treatment of adult humans, dosages of from about 0.25 to 50 mg, preferably from 1 to 30 mg, and most preferably 1 to 20 mg per day may be used. A once a day dosage is normally sufficient, although divided doses may be administered. For treatment of a Bipolar Disorder, a dose range of from 1 to 30 mg, preferably 1 to 20 mg per day is suitable. Radiolabelled olanzapine, can be detected in the saliva and thus the compound can potentially be monitored in patients to assess compliance.
- a preferred formulation of the invention is a solid oral formulation comprising from about 1 to about 20 mg or 1 to 10 mg of olanzapine as an effective amount of the active ingredient.
- the solid oral formulation is contained in packaging materials which protect the formulation from moisture and light.
- suitable packaging materials include amber colored high density polyethylene bottles, amber colored glass bottles, and other containers made of a material which inhibits the passage of light.
- the packaging will include a desiccant pack.
- the container may be sealed with an aluminum foil blister to provide the desired protection and maintain product stability.
- Olanzapine will normally be administered orally or by injection and, for this purpose, it is usually employed in the form of a pharmaceutical composition.
- compositions comprising olanzapine, as active ingredient associated with a pharmaceutically acceptable carrier may be prepared.
- conventional techniques for the preparation of pharmaceutical compositions may be used.
- the active ingredient will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a capsule, sachet, paper or other container.
- the carrier serves as a diluent, it may be solid, semi-solid or liquid material which acts as a vehicle, excipient or medium for the active ingredient.
- the active ingredient can be adsorbed on a granular solid container for example in a sachet.
- compositions of the invention may, if desired, be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient.
- compositions for the treatment of central nervous system conditions may be formulated as tablets, capsules, injection solutions for parenteral use, gel or suspension for transdermal delivery, suspensions or elixirs for oral use or suppositories.
- the compositions are formulated in a unit dosage form, each dosage containing from 0.25 to 25 mg, more usually 1 to 20 mg, of the active ingredient .
- An alternative preferred composition is a unit dosage form containing from 1 to 30 mg.
- the materials for the present invention can be purchased or prepared by a variety of procedures well known to those of ordinary skill in the art.
- Olanzapine can be prepared as described by Chakrabarti in U.S. Patent No 5,229,382 ('382), herein incorporated by reference in its entirety. Further, the following preparations illustrate a method for preparing of the especially preferred Form II olanzapine polymorph.
- Compound characterization methods include, for example, x-ray powder pattern analysis, thermogravimetric analysis (TGA) , differential scanning calorimetery (DSC) , titrametric analysis for water, and H 1 -NMR analysis for solvent content.
- a sub-surface nitrogen sparge line was added to remove the ammonia formed during the reaction.
- the reaction was heated to 120°C and maintained at that temperature throughout the duration of the reaction.
- the reactions were followed by HPLC until ⁇ 5% of the intermediate 1 was left unreacted.
- reaction mixture was allowed to cool slowly to 20°C (about 2 hours) .
- the reaction mixture was then transferred to an appropriate three neck round bottom flask and water bath.
- To this solution with agitation was added 10 volumes reagent grade methanol and the reaction was stirred at 20°C for 30 minutes. Three volumes of water was added slowly over about 30 minutes.
- the reaction slurry was cooled to zero to 5°C and stirred for 30 minutes.
- the product was filtered and the wet cake was washed with chilled methanol. The wet cake was dried in vacuo at 45°C overnight.
- the product was identified as technical olanzapine.
- hydroxypropyl cellulose was dissolved in purified water to form a solution for granulation.
- the remaining hydroxypropyl cellulose (total of 4.0% w/w final tablet weight), which was an extra fine grade, was combined with the olanzapine (1.18% w/w), lactose (79.32% w/w) and a portion of the crospovidone (5% w/w) in a high shear granulator. All ingredients were security sieved prior to addition and dry blended in the granulator. This mixture was then granulated with the hydroxypropyl cellulose solution in the high shear granulator. The granulation was wet sized using standard methods. The wet granulation was then dried in a fluidized bed dryer and sized. The material was then added to a tumble bin mixer.
- the running powders consisting of microcrystalline cellulose (granular) (10% w/w), magnesium stearate (0.5% w/w), and the remainder of the crospovidone were added to the sized granulation. The mixture was blended and compressed with the appropriate tooling on tablet compression equipment.
- Color Mixture White (hydroxypropyl methylcellulose, polyethylene glycol, polysorbate 80, and titanium dioxide) was mixed with purified water to form the coating suspension. Subcoated tablets were divided into approximately equal sections and spray coated with the coating suspension described above. The operation was performed in a perforated coating pan.
- the coated tablets were lightly dusted with carnauba wax and imprinted with appropriate identification.
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL12616296A IL126162A0 (en) | 1996-03-11 | 1996-12-04 | Method for treating bipolar disorder |
AU13307/97A AU734011B2 (en) | 1996-03-11 | 1996-12-04 | Method for treating bipolar disorder |
EA199800819A EA000758B1 (ru) | 1996-03-11 | 1996-12-04 | Способ лечения биполярного расстройства |
CA 2248905 CA2248905A1 (en) | 1996-03-11 | 1996-12-04 | Method for treating bipolar disorder |
BR9612548A BR9612548A (pt) | 1996-03-11 | 1996-12-04 | Método para tratar distúrbio bipolar |
PL96328925A PL328925A1 (en) | 1996-03-11 | 1996-12-04 | Method of treating bipolar disorders |
JP9532570A JP2000506859A (ja) | 1996-03-11 | 1996-12-04 | 双極性障害の処置方法 |
EP96944772A EP0889725A4 (en) | 1996-03-11 | 1996-12-04 | METHOD FOR TREATING BIPOLAR DISORDERS |
NZ326031A NZ326031A (en) | 1996-03-11 | 1996-12-04 | Use of olanzapine in the manufacture of a medicament for treating bipolar disorder |
NO984189A NO984189D0 (no) | 1996-03-11 | 1998-09-11 | Fremgangsmåte for behandling av bipolar forstyrrelse |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1315996P | 1996-03-11 | 1996-03-11 | |
US60/013,159 | 1996-03-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997033577A1 true WO1997033577A1 (en) | 1997-09-18 |
Family
ID=21758606
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/019575 WO1997033577A1 (en) | 1996-03-11 | 1996-12-04 | Method for treating bipolar disorder |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP0889725A4 (pt) |
JP (1) | JP2000506859A (pt) |
KR (1) | KR19990087713A (pt) |
CN (1) | CN1213966A (pt) |
AU (1) | AU734011B2 (pt) |
BR (1) | BR9612548A (pt) |
CZ (1) | CZ290298A3 (pt) |
EA (1) | EA000758B1 (pt) |
HU (1) | HUP9903679A3 (pt) |
IL (1) | IL126162A0 (pt) |
NO (1) | NO984189D0 (pt) |
NZ (1) | NZ326031A (pt) |
PL (1) | PL328925A1 (pt) |
TR (1) | TR199801797T2 (pt) |
WO (1) | WO1997033577A1 (pt) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0958824A3 (en) * | 1998-05-22 | 1999-12-01 | Eli Lilly And Company | Olanzapine (zyprexa) in combination with fluoxetine (prozac), lithium or anticonvulsant for therapy of refractory depression |
EP0966967A3 (en) * | 1998-05-29 | 2000-05-31 | Eli Lilly And Company | Combination therapy of olanzapine (zyprexa) and fluoxetine (prozac) for treatment of bipolar disorder |
WO2000030650A1 (en) * | 1998-11-23 | 2000-06-02 | Sepracor Inc. | Desmethylolanzapine compositions and methods |
WO2000030648A1 (en) * | 1998-11-23 | 2000-06-02 | Sepracor Inc. | 2-hydroxymethylolanzapine compositions and methods |
WO2000030649A1 (en) * | 1998-11-23 | 2000-06-02 | Sepracor Inc. | Pharmaceutical compositions containing olanzapine-n-oxide |
US6960577B2 (en) | 1998-05-22 | 2005-11-01 | Eli Lilly And Company | Combination therapy for treatment of refractory depression |
US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5229382A (en) * | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
US5457101A (en) * | 1994-06-03 | 1995-10-10 | Eli Lilly And Company | Thieno[1,5]benzoidiazepine use |
-
1996
- 1996-12-04 PL PL96328925A patent/PL328925A1/xx unknown
- 1996-12-04 JP JP9532570A patent/JP2000506859A/ja active Pending
- 1996-12-04 EP EP96944772A patent/EP0889725A4/en not_active Withdrawn
- 1996-12-04 WO PCT/US1996/019575 patent/WO1997033577A1/en not_active Application Discontinuation
- 1996-12-04 BR BR9612548A patent/BR9612548A/pt not_active Application Discontinuation
- 1996-12-04 EA EA199800819A patent/EA000758B1/ru not_active IP Right Cessation
- 1996-12-04 CZ CZ982902A patent/CZ290298A3/cs unknown
- 1996-12-04 KR KR1019980707180A patent/KR19990087713A/ko not_active Application Discontinuation
- 1996-12-04 NZ NZ326031A patent/NZ326031A/en unknown
- 1996-12-04 IL IL12616296A patent/IL126162A0/xx unknown
- 1996-12-04 HU HU9903679A patent/HUP9903679A3/hu unknown
- 1996-12-04 AU AU13307/97A patent/AU734011B2/en not_active Ceased
- 1996-12-04 TR TR1998/01797T patent/TR199801797T2/xx unknown
- 1996-12-04 CN CN96180183A patent/CN1213966A/zh active Pending
-
1998
- 1998-09-11 NO NO984189A patent/NO984189D0/no not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5229382A (en) * | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
US5457101A (en) * | 1994-06-03 | 1995-10-10 | Eli Lilly And Company | Thieno[1,5]benzoidiazepine use |
Non-Patent Citations (1)
Title |
---|
See also references of EP0889725A4 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0958824A3 (en) * | 1998-05-22 | 1999-12-01 | Eli Lilly And Company | Olanzapine (zyprexa) in combination with fluoxetine (prozac), lithium or anticonvulsant for therapy of refractory depression |
US6960577B2 (en) | 1998-05-22 | 2005-11-01 | Eli Lilly And Company | Combination therapy for treatment of refractory depression |
EP0966967A3 (en) * | 1998-05-29 | 2000-05-31 | Eli Lilly And Company | Combination therapy of olanzapine (zyprexa) and fluoxetine (prozac) for treatment of bipolar disorder |
US6174882B1 (en) | 1998-11-23 | 2001-01-16 | Sepracor Inc. | 2-hydroxymethylolanzapine compositions and methods |
WO2000030649A1 (en) * | 1998-11-23 | 2000-06-02 | Sepracor Inc. | Pharmaceutical compositions containing olanzapine-n-oxide |
US6121259A (en) * | 1998-11-23 | 2000-09-19 | Sepracor Inc. | Olanzapine-N-oxide compositions and methods |
WO2000030648A1 (en) * | 1998-11-23 | 2000-06-02 | Sepracor Inc. | 2-hydroxymethylolanzapine compositions and methods |
US6346528B1 (en) | 1998-11-23 | 2002-02-12 | Sepracor Inc. | 2-Hydroxymethylolanzapine compositions and methods |
US6348455B1 (en) | 1998-11-23 | 2002-02-19 | Sepracor Inc. | Desmetylolanzapine compositions and methods |
US6468997B2 (en) | 1998-11-23 | 2002-10-22 | Sepracor Inc. | Desmethylolanzapine compositions and methods |
WO2000030650A1 (en) * | 1998-11-23 | 2000-06-02 | Sepracor Inc. | Desmethylolanzapine compositions and methods |
US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
EP3610890A1 (en) | 2012-11-14 | 2020-02-19 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
US10624875B2 (en) | 2012-11-14 | 2020-04-21 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
Also Published As
Publication number | Publication date |
---|---|
AU1330797A (en) | 1997-10-01 |
KR19990087713A (ko) | 1999-12-27 |
JP2000506859A (ja) | 2000-06-06 |
NO984189L (no) | 1998-09-11 |
EA000758B1 (ru) | 2000-04-24 |
TR199801797T2 (xx) | 1998-12-21 |
NO984189D0 (no) | 1998-09-11 |
EP0889725A4 (en) | 2000-01-19 |
CZ290298A3 (cs) | 1999-10-13 |
AU734011B2 (en) | 2001-05-31 |
EP0889725A1 (en) | 1999-01-13 |
HUP9903679A3 (en) | 2001-10-29 |
CN1213966A (zh) | 1999-04-14 |
BR9612548A (pt) | 1999-07-20 |
NZ326031A (en) | 2001-05-25 |
PL328925A1 (en) | 1999-03-01 |
HUP9903679A2 (hu) | 2000-04-28 |
IL126162A0 (en) | 1999-05-09 |
EA199800819A1 (ru) | 1999-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6159963A (en) | Method for treating substance abuse | |
AU734011B2 (en) | Method for treating bipolar disorder | |
AU709181B2 (en) | Method for treating autism | |
US5744470A (en) | Method for treating insomnia | |
EP0900085B1 (en) | Treatment of excessive aggression with olanzapine | |
EP1007050B1 (en) | Olanzapine for treating substance abuse | |
US6274636B1 (en) | Method for treating a tic disorder | |
AU724245B2 (en) | Method for treating insomnia | |
US6071902A (en) | Method for treating excessive aggression | |
CA2248905A1 (en) | Method for treating bipolar disorder | |
GB2305859A (en) | Treatment of obsessive-compulsive disorder | |
GB2305860A (en) | Anti-emetic | |
AU725940C (en) | Method for treating substance abuse | |
MXPA98007431A (en) | Medications to treat the bipo disorder | |
MXPA98007438A (en) | Medications to treat the insom |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 96180183.2 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1998/01797 Country of ref document: TR |
|
ENP | Entry into the national phase |
Ref document number: 2248905 Country of ref document: CA Ref document number: 2248905 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996944772 Country of ref document: EP Ref document number: PV1998-2902 Country of ref document: CZ Ref document number: 1019980707180 Country of ref document: KR Ref document number: 326031 Country of ref document: NZ Ref document number: PA/a/1998/007431 Country of ref document: MX Ref document number: 98-01384 Country of ref document: RO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1199800831 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 199800819 Country of ref document: EA |
|
WWP | Wipo information: published in national office |
Ref document number: 1996944772 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: PV1998-2902 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1019980707180 Country of ref document: KR |
|
WWR | Wipo information: refused in national office |
Ref document number: PV1998-2902 Country of ref document: CZ |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1019980707180 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996944772 Country of ref document: EP |